Yu Yong
Chief Scientific Officer at GNLX
- Sold, on record
- $3.3M
- Dollars the filings state
- Form 4 sales
- 19
- Latest Aug 31, 2026
- Form 144 notices
- 11
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- GNLXGENELUX CorpChief Scientific Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale GNLXUnusualDec 15, 2023 2023
Sold 32,535 shares at $13.16 ($428k)
Yu Yong, VP, Clinical Trial Operations
No 10b5-1 planSold 100% of holdings ($428k position)0 shares left3.1x usual sizeFollows a Form 144Filing
- 2 Form 4 sale GNLXUnusualJun 24, 2024 +192 days
Sold 6,849 shares at $2.12 ($15k)
Yu Yong, VP, Clinical Trial Operations
No 10b5-1 planSold 38.7% of holdings ($38k position)10,869 shares left0.5x usual sizeFiling
- 3 Form 4 sale GNLXNo planMay 12, 2025 +322 days
Sold 5,579 shares at $2.92 ($16k)
Yu Yong, VP, Clinical Trial Operations
No 10b5-1 planSold 10.5% of holdings ($155k position)47,640 shares left0.5x usual sizeFiling
- 4 Form 4 sale GNLXNo planNov 17, 2025 +189 days
Sold 4,192 shares at $3.83 ($16k)
Yu Yong, SVP, Clinical Development
No 10b5-1 planSold 2.8% of holdings ($574k position)145,844 shares left0.4x usual sizeFiling
- 5 Form 4 sale GNLXNo planMar 24, 2026 +127 days
Sold 906 shares at $2.42 ($2k)
Yu Yong, SVP, Clinical Development
No 10b5-1 planSold 0.6% of holdings ($353k position)144,938 shares left0.2x usual sizeFiling
- 6 Form 4 sale GNLXNo planMay 11, 2026 +48 days
Sold 605 shares at $2.97 ($2k)
Yu Yong, Chief Scientific Officer
No 10b5-1 planSold 0.4% of holdings ($446k position)149,706 shares left0.1x usual sizeFiling
- 7 Form 4 sale GNLXNo planAug 4, 2026 +85 days
Sold 653 shares at $2.94 ($2k)
Yu Yong, Chief Scientific Officer
No 10b5-1 planSold 0.2% of holdings ($791k position)268,371 shares left0.3x usual sizeFiling
- 8 Form 4 sale GNLXUnusualAug 31, 2026 +27 days
Sold 9,683 shares at $2.75 ($27k)
Yu Yong, Chief Scientific Officer
No 10b5-1 planSold 3.6% of holdings ($738k position)258,688 shares left10.7x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (30)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | Sep 2, 2026 | GNLX | Chief Scientific Officer | Form 4 sale | 9,683 | $27k | 3.6% | Unusual | SEC |
| Aug 4, 2026 | Aug 4, 2026 | GNLX | Chief Scientific Officer | Form 4 sale | 653 | $2k | 0.2% | No plan | SEC |
| May 11, 2026 | May 12, 2026 | GNLX | Chief Scientific Officer | Form 4 sale | 605 | $2k | 0.4% | No plan | SEC |
| Mar 24, 2026 | Mar 26, 2026 | GNLX | SVP, Clinical Development | Form 4 sale | 906 | $2k | 0.6% | No plan | SEC |
| Nov 17, 2025 | Dec 11, 2025 | GNLX | SVP, Clinical Development | Form 4 sale | 4,192 | $16k | 2.8% | No plan | SEC |
| May 12, 2025 | May 13, 2025 | GNLX | VP, Clinical Trial Operations | Form 4 sale | 5,579 | $16k | 10.5% | No plan | SEC |
| Jun 24, 2024 | Jul 8, 2024 | GNLX | VP, Clinical Trial Operations | Form 4 sale | 6,849 | $15k | 38.7% | Unusual | SEC |
| Dec 15, 2023 | Dec 18, 2023 | GNLX | VP, Clinical Trial Operations | Form 4 sale | 32,535 | $428k | 100.0% | Unusual | SEC |
| Dec 15, 2023 | Dec 15, 2023 | GNLX | Officer | Form 144 notice | 32,535 | $428k | Notice | SEC | |
| Dec 7, 2023 | Dec 8, 2023 | GNLX | VP, Clinical Trial Operations | Form 4 sale | 36,800 | $436k | 53.1% | Unusual | SEC |
| Dec 7, 2023 | Dec 7, 2023 | GNLX | Officer | Form 144 notice | 36,800 | $436k | Notice | SEC | |
| Nov 21, 2023 | Nov 22, 2023 | GNLX | VP, Clinical Trial Operations | Form 4 sale | 18,665 | $192k | 21.2% | Unusual | SEC |
| Nov 20, 2023 | Nov 21, 2023 | GNLX | VP, Clinical Trial Operations | Form 4 sale | 18,135 | $211k | 17.1% | Unusual | SEC |
| Nov 17, 2023 | Nov 17, 2023 | GNLX | Officer | Form 144 notice | 36,800 | $479k | Notice | SEC | |
| Oct 24, 2023 | Oct 25, 2023 | GNLX | VP, Clinical Trial Operations | Form 4 sale | 5,200 | $99k | 4.7% | No plan | SEC |
| Oct 24, 2023 | Oct 24, 2023 | GNLX | Officer | Form 144 notice | 5,200 | $101k | Notice | SEC | |
| Oct 10, 2023 | Oct 11, 2023 | GNLX | VP, Clinical Trial Operations | Form 4 sale | 5,200 | $114k | 4.7% | No plan | SEC |
| Oct 10, 2023 | Oct 10, 2023 | GNLX | Officer | Form 144 notice | 5,200 | $124k | Notice | SEC | |
| Sep 26, 2023 | Sep 27, 2023 | GNLX | VP, Clinical Trial Operations | Form 4 sale | 5,200 | $123k | 4.7% | No plan | SEC |
| Sep 26, 2023 | Sep 26, 2023 | GNLX | Officer | Form 144 notice | 5,200 | $130k | Notice | SEC | |
| Sep 20, 2023 | Sep 21, 2023 | GNLX | VP, Clinical Trial Operations | Form 4 sale | 6,000 | $168k | 5.4% | No plan | SEC |
| Sep 20, 2023 | Sep 20, 2023 | GNLX | Officer | Form 144 notice | 6,000 | $165k | Notice | SEC | |
| Sep 15, 2023 | Sep 18, 2023 | GNLX | VP, Clinical Trial Operations | Form 4 sale | 10,400 | $228k | 8.9% | No plan | SEC |
| Sep 15, 2023 | Sep 15, 2023 | GNLX | Officer | Form 144 notice | 10,400 | $230k | Notice | SEC | |
| Sep 13, 2023 | Sep 15, 2023 | GNLX | VP, Clinical Trial Operations | Form 4 sale | 29,800 | $630k | 21.9% | No plan | SEC |
| Sep 13, 2023 | Sep 13, 2023 | GNLX | Officer | Form 144 notice | 29,800 | $630k | Notice | SEC | |
| Aug 30, 2023 | Aug 30, 2023 | GNLX | Officer | Form 144 notice | 19,800 | $489k | Notice | SEC | |
| Aug 30, 2023 | Aug 30, 2023 | GNLX | VP, Clinical Trial Operations | Form 4 sale | 19,800 | $489k | 12.7% | No plan | SEC |
| Aug 18, 2023 | Aug 22, 2023 | GNLX | VP, Clinical Trial Operations | Form 4 sale | 3,265 | $77k | 2.1% | No plan | SEC |
| Aug 18, 2023 | Aug 18, 2023 | GNLX | Officer | Form 144 notice | 3,274 | $78k | Notice | SEC |